# A Phase 2 Bridging Study to Assess the New Formulation of ETVAX

> **NCT05178134** · PHASE2 · COMPLETED · sponsor: **Scandinavian Biopharma AB** · enrollment: 280 (actual)

## Conditions studied

- Healty Volunteers
- Preventable Disease, Vaccine

## Interventions

- **BIOLOGICAL:** Etvax
- **BIOLOGICAL:** Etvax

## Key facts

- **NCT ID:** NCT05178134
- **Lead sponsor:** Scandinavian Biopharma AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-08
- **Primary completion:** 2022-10-20
- **Final completion:** 2022-10-20
- **Target enrollment:** 280 (ACTUAL)
- **Last updated:** 2025-08-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05178134

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05178134, "A Phase 2 Bridging Study to Assess the New Formulation of ETVAX". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05178134. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*